Koninklijke DSM (RDSMY) Raised to “Hold” at Zacks Investment Research
According to Zacks, “DSM N V ADR is involved in the Chemicals Industry. Their main focus is on base materials, performance materials, materials processing, base chemicals and fine chemicals and coating resins. They are also involved in the exploration and development of oil and natural gas deposits in the North Sea, as well as the licensing of chemical technology and know-how; in addition the company produces ingredients for bakery products. DSM is a world market leader in a number of products, including caprolactam, melamine and EPDM synthetic rubber. “
Several other brokerages have also issued reports on RDSMY. JPMorgan Chase & Co. raised Koninklijke DSM from an underweight rating to a neutral rating in a research note on Thursday, March 9th. Barclays PLC raised Koninklijke DSM from an equal weight rating to an overweight rating in a research note on Friday, January 6th.
Shares of Koninklijke DSM (OTCMKTS:RDSMY) opened at 16.81 on Thursday. Koninklijke DSM has a 1-year low of $13.37 and a 1-year high of $17.88. The firm has a market cap of $11.77 billion, a PE ratio of 18.16 and a beta of 1.31. The company’s 50-day moving average price is $16.37 and its 200 day moving average price is $16.00.
Your IP Address:
Koninklijke DSM Company Profile
Koninklijke DSM N.V. (Royal DSM) is a global science-based company, engaged in offering health, nutrition and materials. The Company’s segments include Nutrition, Performance Materials, Innovation Center and Corporate Activities. Its Nutrition segment includes DSM Nutritional Products and DSM Food Specialties.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Koninklijke DSM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke DSM and related companies with MarketBeat.com's FREE daily email newsletter.